Curis: FDA Grants Orphan Drug Designation To CUDC-907 - Quick Facts

(RTTNews) - Curis Inc. (CRIS) announced the U.S. FDA has granted orphan drug designation to its lead drug candidate, CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma.

CUDC-907 is an oral, dual inhibitor of histone deacetylase and phosphoinositide 3-kinase enzymes that is currently under investigation in Phase 1 clinical studies in patients with relapsed or refractory lymphomas or multiple myeloma as well as in patients with advanced/ relapsed solid tumors, including hormone receptor positive (HR+)/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements.